Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by BIOCODEX Oy in Finland

Tel-Aviv, Israel, January 17, 2018

Neurim Pharmaceuticals (‘Neurim’) and BIOCODEX Oy (‘Biocodex’) announced today a license agreement in which Biocodex will obtain the exclusive marketing rights to market Neurim’s newly developed Rx paediatric product in Finland.

Neurim’s PedPRM, targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases, is expected to be the first sleep drug approved for children.

“We are pleased to expand our partnership with Biocodex and confident in Biocodex Oy ability to bring this much needed treatment to Finland,” said Nava Zisapel, CEO of Neurim Pharmaceuticals. “Our team is working diligently to make our new treatment accessible for the children and their families in additional markets.”

“We are much delighted to build our partnership with Neurim – their development and clinical expertise have led them to be on the frontline on understanding and the treatment of insomnia,” said Tessa Ahosalmi, General Manager of Biocodex Oy.

About PedPRM

PedPRM is a response to the unmet clinical need in the field of paediatric insomnia, specifically developed to address main difficulties in children with ASD and neurogenetic diseases.

PedPRM completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. PedPRM met both the primary and secondary efficacy endpoints demonstrating statistically significant and clinically relevant improvements.

About Neurim Pharmaceuticals

Neurim Pharmaceuticals Ltd.  is a neuroscience pharma company, focusing on discovering and developing innovative drugs for central nervous system diseases. Neurim has a strong and innovative product pipeline, intended for insomnia, Alzheimer’s disease, glaucoma and pain. Its first approved drug, Circadin®, is available in more than 45 countries around the world.

About Biocodex Oy

Biocodex Oy, Finland (www.biocodex.fi) is a subsidiary of a global privately-held, French pharmaceutical company, Biocodex S.A.S.

Biocodex Oy is a sales and marketing company distributing medicines for adult and paediatric patients. It represents and supplies branded and generic medicines, OTC and free sale products to pharmacies and hospitals in Finland, Sweden, Norway, Estonia, Latvia and Lithuania. It also offers partnering and a comprehensive pharmaceutical and medical services for third parties.

 


  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
    • NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD)
    • Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018
  • Partners

    Partners